Article Sidebar

Submitted
May 28, 2021
Published
May 28, 2021
Download
PDF
Statistic
Read Counter : 92 Download : 43

Main Article Content

Abstract

Diarrhea is a common side effect of chemotherapy regimens. Diarrhea can cause depletion of fluids and electrolytes, malnutrition, and dehydration. Chemotherapy-induced diarrhea (CID) can occur in as many as 50-80 percent of patients receiving chemotherapy. Probiotics have been shown effective at preventing diarrhea in inflammatory bowel disease and may prove useful in the oncology setting, Clinical research indicates that probiotics promote a healthy balance of intestinal flora and has immunomodulatory effects in cancer patients and may help minimize some of the negative gastrointestinal side effects associated with treatment. This article reviews the current available scientific literature regarding the effect of Floralite capsules in promoting immune function & As supportive therapy for chemotherapy induced diarrhea.

Keywords

Floralite capsules Immune System Chemotherapy induced diarrhea

Article Details

How to Cite
Govind Shukla, Nagalakshmi Yaparthy, D.Sruthi Rao, & C.J. Sampath Kumar. (2021). FLORALITE Capsules: cancer supportive therapy for chemotherapy-induced diarrhea (CID). International Journal of Research in Pharmacology & Pharmacotherapeutics, 5(4), 306-310. https://doi.org/10.61096/ijrpp.v5.iss4.2016.306-310
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. [1]. Richardson G. and Dobish RJ Oncol.Pharm.Pract. 13(4), 2007, 181-198.
  2. [2]. Wisinski K and Benson A, III. J Support.Oncol. 5(6), 2007, 270-271.
  3. [3]. Alexander Stein, Wieland Voigt and Karin Jordan Ther. Adv. Med. Oncol. 2(1), 2010, 51_63.
  4. [4]. Cassidy J, et al. J Clin Oncol 26, 2008, 2006-2012
  5. [5]. National Cancer Institute, U.S. National Institutes of Health, Common Terminology criteria for adverse events (online).
  6. [6]. Arnold RJ et al. J Support Oncol. 3(3), 2005, 227-232.
  7. [7]. Cherny NI. J Pain Symptom.Manage. 36(4), 2008, 413-423.
  8. [8]. Mitsuoka T. The human gastrointestinal tract. In: Wood BJB, Ed. The Lactic Acid Bacteria. The Lactic Acid Bacteria in Health and Disease. London and New York: AppliedScience; 1992, 69–114.
  9. [9]. Drasar BS, Shiner M, McLeod GM. Studies on the intestinal flora: the bacterial flora of the gastrointestinal tract in healthy and achlorhydric persons. Gastroenterology.56, 1969, 71–79.
  10. [10]. Haller D, Blum S, Bode C, et al. Effects of Lactobacillus acidophilus strain L-55 on experimental allergic rhinitis in BALB/c mice. Infect Immun 68, 2000, 752–759.
  11. [11]. Meydani SN & Ha WK Immunological effects of yogurt.Am J Clin Nutr 71, 2000, 861–872.
  12. [12]. Asano M, Karasawa E & Takayama T Antitumor activity of Lactobacillus casei (LC 9018) against experimental mouse bladder tumor (MBT-2). J Urol 136, 1986, 719–721.
  13. [13]. McIntosh GH, Royle PJ & Playne MJ A probiotic strain of L. acidophilus reduces DMH-induced large intestinal tumors in male Sprague-Dawley rats. Nutr Cancer 35, 1999, 153–159.
  14. [14]. Goldin BR, Gorbach SL: Alterations of the intestinal microflora by diet, oral antibiotics, and Lactobacillus: decreased production of free amines from aromatic nitro compounds, azo dyes, and glucuronides. J NatlCancer Inst, 73, 1984, 689-695.
  15. [15]. (Gibson, R.J. and Stringer, A.M. Chemotherapy-induced diarrhoea. Curr Opin Support Palliat Care 3, 2009, 3135.)
  16. [16]. . Keefe, D.M., Gibson, R.J. and Hauer-Jensen, M. Gastrointestinal mucositis. Semin Oncol Nurs 20, 2004, 3847.
  17. [17]. Stringer, A.M, et.al. Faecal microflora and beta-glucuronidase expression are altered in an irinotecan-induced diarrhea model in rats. Cancer Biol Ther 7, 2008, 1919-1925.
  18. [18]. Roy D, Ward P, Vincent D, Mondou F. Molecular identiłcation of potentially probiotic Lactobacilli. Curr Microbiol 40, 2000, 40-46.
  19. [19]. Kullen MJ, Klaenhammer TR. Genetic modiłcation of intestinal Lactobacilli and Biłdobacteria. Curr Issues Mol Biol 2, 2000, 41-50.
  20. [20]. Lawton, E.M., Ross, R.P., Hill, C. and Cotter, P.D. Two-peptide lantibiotics: a medical perspective. Mini Rev Med Chem 7, 2007, 1236-1247.
  21. [21]. Oberreuther-Moschner DL, Jahreis G, et.al. Dietary intervention with the probiotics Lactobacillus acidophilus 145 and Biłdobacterium longum 913 modulates the potential of human faecal water to induce damage in HT29clone19A cells. Br J Nut, 91, 2004, 925-932
  22. [22]. Ohara T, Yoshino K, Kitajima M. Possibility of preventing colorectal carcinogenesis with probiotics. Hepatogastroenter- ology, 57, 2010, 1411-1415.
  23. [23]. Willard T, Chiron Consultants Inc., Calgary, Canada. Unpublished Research, 1989.
  24. [24]. Stein A, Voigt W, Jordan K. Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management. Ther Adv Med Oncol, 2, 2010, 51-63.
  25. [25]. Prisciandaro LD, Geier MS, Butler RN, et al. Evidence supporting the use of probiotics for the prevention and treatment of chemotherapy-induced intestinal mucositis. Crit Rev Food Sci Nutr, 51, 2011, 239-247
  26. [26]. Abd El-Atti S, Wasicek K, Mark S, Hegazi R. Use of probiotics in the management of chemotherapy-induced diarrhea: a case study. JPEN J Parenter Enteral Nutr, 33, 2009, 569-570.
  27. [27]. Chitapanarux I, Chitapanarux T, Traisathit P, et al. Randomized controlled trial of live Lactobacillus acidophilus plus Biłdobacterium biłdum in prophylaxis of diarrhea during radiotherapy in cervical cancer patients Radiat Oncol, 5, 2010, 31.
  28. [28]. Marteau PR, de Vrese M, Cellier CJ, Schrezenmeir J. Protection from gastrointestinal diseases with the use of probiotics. Am J Clin Nutr, 73, 2001, 430S-436S
  29. [29]. Urbancsek H, Kazar T, Mezes I, Neumann K. Results of a double-blind, randomized study to evaluate the emcacy and safety of Antibiophilus in patients with radiation-induced diarrhoea. Eur J Gastroenterol Hepatol, 13, 2001, 391-396.
  30. [30]. Fernandez MF, Boris S, Barbes C. Probiotic properties of human Lactobacilli strains to be used in the gastrointestinal tract. J Appl Microbiol, 94, 2003, 449-455.
  31. [31]. Honma N. On eVects of lactic acid bacteria. Part I. Biological signiłcance. New Med Clin, 35, 1986, 2687-2695.
  32. [32]. Yoneda K. Biological study on live bacteria products in the market. Med Pharmacol 17, 1987, 1529-1534.
  33. [33]. Lin, Y.P., Thibodeaux, C.H.,et.al. Probiotic Lactobacillus reuteri suppress proinflammatory cytokines via c-Jun. Inflamm Bowel Dis 14, 2008, 1068-1083.
  34. [34]. Vanderpool, C., Yan, F. and Polk, D.B. Mechanisms of probiotic action: Implications for therapeutic applications in inflammatory bowel diseases. Inflamm Bowel Dis 14, 2008, 1585-1596.
  35. [35]. Maria-Aggeliki KS, Nikolaos KL, Kyrias GM, Vassilis KE. The potential clinical impact of probiotic treatment for the prevention and/or anti-inammatory therapeutict against radiation induced intestinal mucositis. A review Recent Pat Inamm Allergy Drug Discov, 3, 2009, 195-200
  36. [36]. Zwielehner J, Lassl C, Hippe B, et al. Changes in human fecal microbiota due to chemotherapy analyzed by TaqMan-PCR 454 sequencing and PCR-DGGEngerprinting. PLoS One, 6, 2011.